http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2494708-C1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c9e08e51f7fdfb77bf78451526ab3442
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_58fd5382b83a8cca9d5a06d5a6aa73ea
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_259b4bf6a782b8aa39cad6b2545b4a77
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_de3472d1a57389e3f57c099d95af705b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e1f4791e3ad955a7c772ebb867d0ebc9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_35387665bf88d723cc27402e99cfcafb
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61H39-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61N2-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-50
filingDate 2012-06-09-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2013-10-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3983968672c296d6f58d00c5771063c8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_92dea73be77b48a754db2df636c4a874
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b56072aede7d1a0d5f26ffc630d6bdd9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9ca4122be2b8e89e2d9cf04da9e8b3bd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_75b0e06a7d88902b48d72d6bbc30c1ef
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b9cfe3198b0f49fbd69374a0d5163786
publicationDate 2013-10-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber RU-2494708-C1
titleOfInvention Method of treating progressing myopia in children
abstract FIELD: medicine. n SUBSTANCE: invention relates to medicine, namely to ophthalmology and pediatrics, and can be used for treatment of progressing myopia in children. For this purpose homeopathic medication placenta compositum is introduced into acupuncture points BL1 (UB1), ST1, EX-HN7(QIUHOU), GB1, EX-HN4(YUYAO) in dose 0.2 ml into each point. After that head area is subjected to exposure to pulse low-frequency electromagnetic field (PLEMF). Course of treatment constitutes 10 procedures, performed every second day. n EFFECT: method ensures reduction of rate of myopia progress and elimination of impairment in regional hemodynamics of eye, developed as a result of existing for a long time myopic defocus, at the background of stabilisation of processes of cell metabolism in connective tissue. n 2 ex
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2626578-C1
priorityDate 2012-06-09-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2329029-C1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2371146-C1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2306919-C1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10133
http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID69266
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419479630
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID69266

Total number of triples: 33.